Simple, single-dose nasal spray offers greater ease and comfort of administration ;  positioning AdCOVID as a differentiated vaccine candidate for adults and children AdCOVID is capable of stimulating a n additional and specialized type of immunity – local nasal mucosal immunity – believed to be

GAITHERSBURG, Md. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual

AdCOVID , a Single-dose Intranasal Vaccine for COVID-19   is Designed to Generate a   Broad Immune Response Against COVID-19 with the Unique Ability to Promote   Nasal Mucosal Immunity Lonza Agreement Builds on Existing Partnerships and Expands Altimmune’s Commercial Readiness in Preparation to

GAITHERSBURG, Md. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update. “2020 has been a transformational year for

GAITHERSBURG, Md. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020 . Altimmune management will host a conference call for

GAITHERSBURG, Md. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual

Comprehensive analysis shows AdCOVID uniquely   stimulates three key immune compon ents: serum neutralizing antibody , T cell responses , and mucosal immunity in the respiratory tract Nasal m ucosal i mmunity   may be the c ritical factor in   driving sterilizing immunity and p reventing f urther s

GAITHERSBURG, Md. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October: H.C. Wainwright 4 th Annual NASH Investor Conference

GAITHERSBURG, Md. , Sept. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Scot Roberts , Ph.D., Chief Scientific Officer of Altimmune, Inc. , presented an overview of the Company’s AdCOVID and T-COVID intranasal vaccine

Company anticipates first-in-human trials to start in Q4 2020 GAITHERSBURG, Md. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of multiple dose toxicity and toxicokinetic studies of ALT-801, a